M&A / Deals Pathos AI signs two cancer deals with Alphamab and AZ PharmaphorumPathos AI has grown its oncology pipeline by licensing a bispecific ADC from Alphamab for $125m and partnering a breast cancer drug from AstraZeneca.OncologyRead full story pharminent August 4, 2026 (Last updated: August 8, 2026) Pharmaphorum Pathos AI has grown its oncology pipeline by licensing a bispecific ADC from Alphamab for $125m and partnering a breast cancer drug from AstraZeneca. Oncology Read full story Post navigation Previous: AstraZeneca and Bristol Myers Squibb Reported to Have Held Mega-Merger TalksNext: Supernus and Indivior merge to create scaled, CNS-focused entity Related Stories M&A / Deals China’s Haisco forms immunology biotech with up to $1.5B from American VCs pharminent August 25, 2026 M&A / Deals Roche commits to lean-mass preservation with Hanmi obesity deal pharminent August 24, 2026 M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026
